Simeprevir

Phase 3

Johnson & Johnson (JNJ)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Hepatitis C Virus Infection

View Full Landscape

Drug Information

Target Indication

Hepatitis C Virus Infection

Clinical Trial

NCT02114151

Last updated: 1/24/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA5/14/2014

Olysio

Olysio is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adult patients. For hepatitis C virus (HCV) genotype specific activity.

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

JNJ

Johnson & Johnson

Pharmaceutical Preparations•North America•NYSE

Related Pipeline

galantamine ERPhase 3

Alzheimer's Disease

Test acetaminophenPhase 3

Post-operative Dental Pain

CG 5503;tapentadolPhase 3

Osteoarthritis

tapentadol (CG5503) ERPhase 3

Low Back Pain

levofloxacinPhase 3

Pneumonia

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts